PharmaCyte Biotech, Inc. (PMCB) — Financial statements
Income statement, balance sheet, and cash flow for PharmaCyte Biotech, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 0.44↑7.6% | 0.41↓13.0% | 0.47↓32.2% | 0.69↓24.6% | 0.92 | |
| General & Administrative Expenses | 4↓17.8% | 5↑0.8% | 5↑120.4% | 2↓20.3% | 3 | |
| Selling & Marketing Expenses | 0.00↓100.0% | 1↑7.0% | 1↓20.1% | 2 | 0.00 | |
| SG&A Expenses | 4↓35.6% | 6↑2.1% | 6↑61.8% | 4↑36.7% | 3 | |
| Other Expenses | 0.00↑100.0% | -0.00↑98.4% | -0.00↓3428.6% | -0.00↑94.4% | -0.00 | |
| Operating Expenses | 4↓32.9% | 7↑1.0% | 6↑47.0% | 4↑21.2% | 4 | |
| Total Costs & Expenses | 4↓32.9% | 7↑1.0% | 6↑47.0% | 4↑21.2% | 4 | |
| Operating Results | ||||||
| Operating Income | -4↑32.9% | -7↓1.0% | -6↓47.0% | -4↓21.2% | -4 | |
| Depreciation & Amortization | 0.00↓100.0% | 7↑1.0% | 6 | 0.00 | 0.00 | |
| EBITDA | 31↑347.3% | 7↑258.8% | -4↓1.8% | -4↓19.5% | -4 | |
| EBIT | 31↑9085.0% | 0.33↑105.2% | -6↓52.3% | -4↓19.5% | -4 | |
| Interest & Other Income | ||||||
| Net Interest Income | 1↓58.4% | 3↑75.4% | 2↑1133.0% | 0.16↑5265.5% | -0.00 | |
| Interest Income | 1↓58.4% | 3↑75.5% | 2↑1128.7% | 0.16↑5185590.8% | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00↓100.0% | 0.00↓83.3% | 0.00 | |
| Non-Operating Income | -35↓411.2% | -7↓220.3% | -2↓1298.4% | -0.15↓104.6% | -0.07 | |
| Other Income / Expenses | 35↑411.2% | 7↑220.3% | 2↑1300.0% | 0.15↑113.1% | 0.07 | |
| Income Before Tax | 31↑9085.0% | 0.33↑107.7% | -4↓1.8% | -4↓19.4% | -4 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 31↑9085.0% | 0.33↑107.7% | -4↓1.8% | -4↓19.4% | -4 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 31↑9085.0% | 0.33↑107.7% | -4↓1.8% | -4↓19.3% | -4 | |
| Bottom-Line Net Income | 23↑235.5% | -17↓299.4% | -4↓1.8% | -4↓19.4% | -4 | |
| EPS (Basic) | 3.19↑277.2% | -1.80↓718.2% | -0.22↑18.5% | -0.27↑89.0% | -2.46 | |
| EPS (Diluted) | 3.19↑277.2% | -1.80↓116.9% | -0.83↓5.1% | -0.79↑67.9% | -2.46 | |
| Weighted Average Shares | 7↓23.5% | 10↓50.8% | 19↑25.6% | 16↑972.0% | 1 | |
| Weighted Average Diluted Shares | 7↓23.5% | 10↑85.0% | 5↑0.0% | 5↑257.6% | 1 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.